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Background: The standard treatment for stage IV gastric cancer is chemotherapy, but outcomes remain poor. The
effectiveness of induction chemotherapy followed by surgery in selected patients who had a good response to
chemotherapy is unclear.
Methods: A total of 59 patients with stage IV gastric cancer received induction chemotherapy with S-1 and
cisplatin. In each cycle, oral S-1 (80 mg/m2) was administered for 3 weeks, followed by a 2-week drug holiday.
Intravenous cisplatin (60 mg/m2) was administered on day 8 after adequate premedication and hydration. If
unresectable features resolved after chemotherapy, patients underwent curative (R0) resection. The safety and
outcomes of this treatment combination were evaluated, and predictive factors for survival were determined.
Results: Thirteen of 59 patients (22%) were eligible for R0 resection after induction chemotherapy. Kaplan-Meier
analysis showed an overall median survival time of 13 months and a 3-year survival rate of 18.2%. Among patients
who underwent R0 resection, the median survival time was 53 months and the 3-year survival rate was 53.8%. Multivariate
analyses showed that negative para-aortic lymph nodes and undergoing R0 resection were independent predictors
of survival.
Conclusions: Treatment of stage IV gastric cancer with S-1 and cisplatin induction chemotherapy followed by R0
resection is safe and may improve survival compared with chemotherapy alone. Further study of this
dual-modality therapy is warranted.
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According to the World Health Organization cancer sta-
tistics, gastric cancer is the second most common malig-
nancy worldwide, and the fourth most common cause of
cancer mortality [1,2]. Surgical resection is the preferred
treatment for gastric cancer, but approximately two-thirds
of patients have unresectable disease at the time of diag-
nosis [3]. Patients with advanced disease may present with
local invasion, peritoneal dissemination, hepatic metasta-
sis, or para-aortic lymph node metastasis. Prognosis in
these patients is poor, with a median survival time of 3 to
5 months without treatment [4,5] and a reported 5-year
survival rate of 9.4% [2].* Correspondence: msaito@jichi.ac.jp
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unless otherwise stated.The current standard treatment for stage IV gastric
cancer is systemic chemotherapy [6,7]. The prognosis
has gradually improved because of advances in chemo-
therapy regimens, but is not yet satisfactory, and per-
manent cure is rarely achieved. In Japan, combination
induction chemotherapy using S-1 and cisplatin is the
current standard treatment for unresectable gastric cancer,
based on the results of the SPIRITS (S-1 and cisplatin ver-
sus S-1 alone for first-line treatment of advanced gastric
cancer) trial [8].
Recently, various multimodality therapies including
chemotherapy, radiotherapy, and surgery have been in-
vestigated in an effort to improve outcomes. For resect-
able tumors, preoperative chemotherapy reduces tumor
size, treats micrometastases, and increases the rate of
curative (R0) resection. Some authors have reportedhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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chemotherapy followed by surgery [9-15], but the effi-
cacy of combining current chemotherapy regimens with
surgery in selected patients remains unclear.
This study reviewed patients with stage IV gastric cancer
who were treated with induction chemotherapy using S-1/
cisplatin followed by R0 resection in selected patients who
responded well to chemotherapy, to evaluate the safety
and outcomes of this treatment combination, and identify
predictive factors for survival.
Methods
Inclusion and exclusion criteria
Patients with unresectable stage IV gastric cancer who
were treated at the Saitama Medical Center, Jichi Medical
University, Japan from January 2008 to March 2010 were
retrospectively reviewed. Inclusion criteria for the study
were: (1) gastric cancer diagnosed by upper gastrointes-
tinal endoscopy and histologically confirmed as adenocar-
cinoma; (2) unresectable features detected on thoracic,
abdominal, or pelvic multidetector computed tomography
(CT) scan; (3) ability to maintain an oral liquid or solid
intake without vomiting; (4) Eastern Cooperative On-
cology Group Performance Status (ECOG PS) 0 or 1;
and (5) white blood cell count ≥ 3,000/ml, platelet
count ≥100,000/ml, serum creatinine ≤ 1.2 mg/dl, as-
partate aminotransferase (AST) < 70 IU/l, and alanine
aminotransferase (ALT) < 70 IU/l. Unresectable fea-
tures were defined as: invasion of the primary lesion
into adjacent organs (T4), ascites or peritoneal nodules
(P1), para-aortic lymph node metastasis (N3), bulky
lymph node metastasis or invasion into the area
around the celiac trunk (bulky N2), or hepatic metasta-
sis (H1). Exploratory laparoscopy was recommended
for diagnosis of peritoneal dissemination, but was not
mandatory. Peritoneal dissemination was diagnosed by
imaging by a specialist in radiological interpretation.
Exclusion criteria were: (1) prior history of gastric can-
cer treatment; and (2) known distant metastasis to sites
other than the lymph nodes, liver or peritoneum. Pa-
tients were not routinely investigated for distant me-
tastasis, but those with symptoms suggestive of
metastasis underwent appropriate investigations. The
gross and histological tumor types, depth of tumor inva-
sion, and lymph node metastasis (TNM) stage were de-
scribed according to the Japanese Classification of Gastric
Carcinoma (JCGC; 13th edition) of the Japanese Gastric
Cancer Association [16]. This study was approved by the
Research Ethics Committee at Jichi Medical University.
Induction chemotherapy and evaluation of response
All patients received induction chemotherapy using S-1
and cisplatin according to the protocol described in the
SPIRITS trial [8]. In each cycle, oral S-1 (80 mg/m2) wasadministered for 3 weeks followed by a 2-week drug holi-
day. Intravenous cisplatin (60 mg/m2) was administered
on day 8 after adequate premedication and hydration.
Complete blood cell count, and serum creatinine, total
bilirubin, AST and ALT levels were measured before
each cycle and regularly during each cycle. Chemother-
apy toxicity was evaluated according to the National
Cancer Institute Common Toxicity Criteria for Adverse
Events (NCI CTCAE) version 3.0. If grade 4 leukopenia or
grade 3 or 4 thrombocytopenia were observed, the S-1
and cisplatin doses were reduced by 1 dose level. If the
serum creatinine level exceeded 1.5 mg/dl, cisplatin was
discontinued and S-1 monotherapy was continued.
Response was assessed after every two cycles of chemo-
therapy. Measurable tumors were evaluated using the
Response Evaluation Criteria in Solid Tumors (RECIST)
[17]. The best overall response was evaluated and the re-
sponse was not confirmed for 4 weeks. The primary gastric
lesion was assessed using endoscopy, gastroduodenal barium
contrast study, or CT scan according to the JCGC criteria.
Surgical intervention and follow-up chemotherapy
If the unresectable features were resolved at the time of
reassessment, surgery was performed 4 to 6 weeks after
completion of S-1 administration. Informed consent was
obtained from all patients. If surgical exploration in
these patients did not reveal unresectable features, R0
resection was performed. Patients underwent total or
distal gastrectomy according to the location of the gas-
tric tumor with D2 lymph node dissection, plus ex-
tended para-aortic lymph node dissection (PAND) if
they were para-aortic lymph node-positive (cN3) at pres-
entation. If surgical exploration revealed unresectable
features, exploratory laparotomy or bypass surgery was
performed. Postoperative follow-up included blood test-
ing every 3 months and abdominal ultrasonography
every 6 months. Patients also underwent yearly abdom-
inal CT scans and upper gastrointestinal endoscopy.
Response to induction chemotherapy, surgical proced-
ure, extent of lymph node dissection, intraoperative blood
loss, postoperative complications, pathological examin-
ation, and final disease stage were recorded. The thera-
peutic response was graded according to histological
features. Survival was defined as the time from the start of
induction chemotherapy until death or the last follow-up.
Survival data were updated to December 2013.
Patients who underwent R0 resection received S-1
alone as postoperative adjuvant chemotherapy for 1 year.
The remaining patients continued to receive S-1 and cis-
platin therapy until disease progression was evident.
When postoperative recurrence was found or the tumor
was refractory to S-1 and cisplatin, irinotecan monother-
apy (100 mg/m2 intravenously on days 1, 8 and 15) was
administered as second-line treatment and paclitaxel
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15) was administered as third-line treatment, and con-
tinued until an adverse effect occurred or further disease
progression was confirmed. Twenty-nine patients re-
ceived second-line treatment and 12 received third-line
treatment.
Statistical analysis
Overall survival rates for the whole group and for the R0
resection group were analyzed using the Kaplan-Meier
method. Prognostic factors for survival were analyzed
with univariate and multivariate analyses using the Cox
proportional hazards model. All reported P-values were
2-sided, and P < 0.05 was considered to be statistically
significant. Statistical analyses were performed using
SPSS version 22.0 (SPSS, Chicago, IL, USA).
Results
Patient characteristics
Of the 88 patients with stage IV gastric cancer who were
treated at our institute during the study period, 59 (45
male and 14 female) met the inclusion criteria. The me-
dian age of patients was 65 years (40 to 74 years). ECOG
PS was 0 in 46 patients and 1 in 13 patients. Thirty pa-
tients had differentiated adenocarcinoma and 29 had un-
differentiated adenocarcinoma. Preoperative laparoscopy
was performed in 10 patients, but the results did not in-
fluence subsequent management. The frequencies of fea-
tures that deemed the tumor to be unresectable are
shown in Table 1.
Clinical response to induction chemotherapy
According to the RECIST criteria, 35 of the 59 patients
had metastatic lesions detected on abdominal CT scan
before induction chemotherapy (lymph node metastasis
in 28 patients and liver metastasis in 7). Of these 35 pa-
tients, 13 (37.1%) responded to chemotherapy (9 patients
had a partial response and 4 had a complete response).
Overall, patients received 1 to 8 cycles (median 4 cycles)
of induction chemotherapy with S-1 and cisplatin. Pa-
tients who underwent surgery received 2 to 10 cycles
(median 2 cycles) of induction chemotherapy (Table 2).
According to the JCGC criteria, 30 of the 59 patients
(50.8%) responded to chemotherapy. The primary lesionTable 1 Factors making tumors unresectable at baseline
Factor N
Direct invasion into adjacent organs 9
Para-aortic lymph node metastasis 21
Bulky N2 lymph nodes 7
Liver metastasis 7
Peritoneal metastasis 26showed a partial response in 28 patients and a complete
response in 2. Table 3 shows the adverse effects of in-
duction chemotherapy treatment. Nineteen patients
(32.2%) had grade 3 adverse effects, and no patients had
grade 4 effects. There were no treatment-related deaths.
Surgical outcomes
Sixteen patients were deemed eligible for surgery be-
cause of resolution of the factors that had made their
cancer unresectable. Of these sixteen patients, four pre-
sented with cN3, four with bulky N2, six with cP1, and
two with cT4 cancer. Of the six patients with cP1, three
were found to have residual peritoneal seeding at the
time of surgery, which made them ineligible for R0 re-
section. Two of these three underwent bypass surgery only
and one underwent exploratory laparotomy only. The
remaining 13 patients underwent R0 resection, resulting
in an R0 resection rate of 22% (13/59). The details of sur-
gery are shown in Table 4. We found no correlation be-
tween histological response and clinical outcome.
Patient survival
At the time of analysis in December 2013, 34 of the 59
patients had died, and the median follow-up period of
the remaining 25 patients was 26 months (range 1 to
63 months). Kaplan-Meier analysis showed an overall
median survival time of 13 months and a 3-year survival
rate of 18.2% (Figure 1). Multivariate analyses identified
negative para-aortic lymph nodes (hazard ratio (HR)
0.086, 95% confidence interval (CI) 0.020 to 0.383, P =
0.002) and undergoing R0 resection (HR 0.285, 95% CI
0.131 to 0.623, P < 0.001) as independent prognostic fac-
tors for survival (Table 5). Age, sex, T stage, bulky N2,
peritoneal metastasis, distant metastasis, response ac-
cording to the JCGC criteria, and second-line chemo-
therapy were not significantly associated with survival.
Among the patients who underwent R0 resection, six
developed recurrence (three with para-aortic lymph
node, and three with peritoneal dissemination). All pa-
tients with recurrence received chemotherapy but they all
died: one each with lung metastasis at 15 months, brain
metastasis at 12 months, liver metastasis at 31 months,
lymph node recurrence at 36 months, peritoneal dissemin-
ation at 24 months, and peritoneal dissemination at
28 months) (Table 2). Kaplan-Meier analysis of patients
who underwent R0 resection showed a mean survival time
of 53 months and a 3-year survival rate of 53.8% (Figure 2).
Discussion
In Japan, S-1 and cisplatin combination chemotherapy is
the standard treatment for stage IV gastric cancer, based
on the results of the SPIRITS trial [8]. Although the selec-
tion of chemotherapy regimen in P1 patients requires par-
ticular care because of potential gastrointestinal symptoms
Table 2 Details of the 13 patients who underwent R0 resection
Case Unresectable factor Induction chemotherapy (course) Final stage Postoperative chemotherapy Survival Relapsed site
1 N3 3 IV Paclitaxel Dead LN
2 N3 2 IIIB S-1 Alive -
3 N3 2 IV UFT Dead LN
4 T4 2 IIIA S-1 Alive -
5 T4 2 IV - Dead P
6 BulkyN2 2 IIIB S-1 Alive -
7 BulkyN2 2 IIIB - Alive -
8 N3 2 IV UFT Dead LN
9 BulkyN2 2 IIIB S-1 Alive -
10 P1 3 IV - Dead P
11 P1 6 IIIA S-1 Alive -
12 BulkyN2 2 IIIA - Alive -
13 P1 10 IV - Dead P
H1, hepatic metastasis; LN, lymph nodes; bulky N2, bulky lymph node metastasis or invasion into the area around the celiac trunk; N3, para-aortic lymph node
metastasis; P, peritoneum; P1, ascites or peritoneal nodules; T4, invasion of the primary lesion into adjacent organs, UFT, tegafur- uracil.
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considered to be appropriate for the patients in this study
because such patients were also included in the SPIRITS
trial. As shown in Table 3, serious adverse events associ-
ated with induction chemotherapy occurred at rates similar
to those in the SPIRITS trial. The SPIRITS trial showed a
median overall survival time of 13.0 months, which is simi-
lar to the median overall survival time of 15.0 months in
the present study.
In patients with resectable gastric cancer, preoperative
chemotherapy has the following advantages: (1) possible
prolonged survival and recurrence-free survival due to
eradication of micrometastases; (2) antitumor effects on
the primary lesion and lymph node metastases; (3) down-
staging, allowing less-invasive surgery; (4) better compli-
ance than with postoperative chemotherapy; (5) superior
drug delivery and penetration in the presence of tumor-Table 3 Adverse effects of induction chemotherapy
Toxicity grade
(NCI-CTC)
Total (%) Grade 3/4 (%)
1 2 3 4
Leukopenia 8 17 4 0 49.2 6.8
Neutropenia 2 15 0 0 28.8 0
Thrombocytopenia 6 2 0 0 13.6 0
Anemia 7 5 2 0 23.7 3.4
Anorexia 21 11 0 0 54.2 0
Nausea 15 6 8 0 49.2 13.6
Vomiting 6 4 3 0 22.0 5.1
Diarrhea 7 1 2 0 16.9 3.4
Abbreviation: National Cancer Institute Common Toxicity Criteria for
Adverse Events.feeding blood vessels and lymphatic channels; (6) clarifi-
cation of the sensitivity of the tumor to chemotherapeu-
tic agents; and (7) confirmation of the presence or
absence of new lesions [18]. These advantages raise the
possibility that some patients who respond well to
chemotherapy may benefit from subsequent R0 resec-
tion. It is clear that a combination of surgery and
chemotherapy is advantageous in resectable gastric can-
cer, but the outcome of this dual-modality treatment in
stage IV gastric cancer treated with S-1 and cisplatin
chemotherapy is still unclear. There is concern that






Dissection of lymph nodes
D2 5
D2 + para-aortic 8
Operative time (minutes), range 235 (40 to 320)
Blood loss (ml) , range 210 (85 to 550)
Blood transfusion 1
Of the 13 patients who underwent R0 resection, 2 (15%) developed
postoperative complications. According to the NCI CTCAE, grade 2 wound
infection and grade 3 intra-abdominal abscess due to a pancreatic fistula
occurred in 1 patient each. There was no postoperative in-hospital mortality.
Figure 1 Kaplan-Meier curve of overall survival (n = 59). Figure 2 Kaplan-Meier curve of survival in patients who
underwent R0 resection (n = 13).
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changes may interfere with tissue dissection, and that ac-
curate staging before chemotherapy is difficult.
In the present study, 22% of patients were deemed eli-
gible for R0 resection after chemotherapy. The only se-
vere postoperative complication was an intra-abdominal
abscess due to a pancreatic fistula (grade 3) in one pa-
tient. The operative time and blood loss were compar-
able to those of conventional R0 resection, suggesting
that gastrectomy can safely be performed after induction
chemotherapy. Previously reported cases of patients who
underwent gastrectomy following S-1 and cisplatin induc-
tion chemotherapy had similar results [9-13]. In the present
study, patients who underwent R0 resection had a 3-year
survival rate of 53.8%, which is similar to that reported in aTable 5 Results of multivariate analyses of associations
between patient characteristics and survival (Cox
proportional hazards model)
Variable P
R0 surgery (+/–) < 0.001
Para-aortic lymph node metastasis (negative/positive) 0.002
Age (years) (≤59/≥ 60) 0.790
Sex (male/female) 0.115
T stage (T2, T3/T4) 0.936
Bulky N2 (−/+) 0.855
Peritoneal metastasis (P0/P1) 0.358
Liver metastasis (H0/H1) 0.125
Distant metastasis (M0/M1) 0.913
Response (JCGC criteria) (CR, PR/SD, PD) 0.182
Second-line chemotherapy (+/–) 0.546
Abbreviations: CR complete response, PD progressive disease, JCGC Japanese
Classification of Gastric Carcinoma, SD stable disease, PR partial response.previous study of stage IV gastric cancer patients who re-
ceived chemotherapy followed by surgery [13].
The REGATTA study is an ongoing phase III con-
trolled trial comparing gastrectomy + postoperative chemo-
therapy and chemotherapy alone. Interim analysis showed
that overall survival of the gastrectomy + postoperative
chemotherapy group was lower than that of the chemother-
apy alone group (HR: 1.08, 95% CI: 0.74 to 1.58). Debulking
surgery for gastric cancer was unsuccessful, except when it
aimed for R0 resection.
The JCOG9501 trial showed that prophylactic D2 node
dissection + PAND in patients with negative para-aortic
lymph nodes did not improve 3- and 5-year survival rates
compared with D2 node dissection alone, leading to the
conclusion that prophylactic PAND should not be per-
formed for curable advanced gastric cancer [19]. However,
the JCOG9501 trial did not include data on patients who
were positive for para-aortic lymph nodes who had re-
ceived induction chemotherapy. Further studies are there-
fore needed to clarify the significance of PAND following
induction chemotherapy.
In the present study, multivariate analyses identified
negative para-aortic lymph nodes and undergoing R0 re-
section as independent prognostic factors for survival.
However, para-aortic lymph node status cannot be defini-
tively determined preoperatively, and therefore cannot be
used to determine which patients are likely to benefit from
R0 resection. Prolonged survival times were expected in
the group undergoing R0 resection, because this group
had the best response to chemotherapy. Overall survival
in the present study was similar to that reported in the
SPIRITS trial, thus, it is not yet clear if adding surgery to
the treatment protocol provides a survival benefit. Further
studies with larger patient numbers and longer follow-up
periods are required to evaluate this.
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cussed. This was a retrospective review of patients who
received treatment, and there was no control group for
comparison. Patient numbers were small, and long-term
follow-up was not available. In this study, 26 patients
had peritoneal metastasis. However, laparoscopy was
performed only in 10 patients for various reasons. Peri-
toneal dissemination was diagnosed in the other 16
patients by imaging by a specialist in radiological inter-
pretation. However, without laparoscopy, it is not easy
to determine whether peritoneal metastases are present
clinically. It seems that staging laparoscopy is necessary
for preoperative precise diagnosis of peritoneal dissem-
ination. There was considerable heterogeneity among
the patients in our study. However, our results suggest
that surgery is safe, and that the possibility of pro-
longed survival after surgery should be further investi-
gated. Further studies with longer term follow-up are
needed to assess the safety and effectiveness of this
combination therapy.
Conclusions
Treatment of stage IV gastric cancer with S-1 and cis-
platin induction chemotherapy followed by R0 resection
is safe and may improve survival compared with treat-
ment with chemotherapy alone. Further study of this
dual-modality therapy is warranted.
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